Infinity Pharmaceuticals, Inc. announced that Jeffery Kutok, M.D., Ph.D. has been promoted to the role of chief scientific officer, effective immediately. In this role, Dr. Kutok will be responsible for overseeing biology and translational science efforts, including preclinical collaborations, to support the ongoing clinical development of IPI-549, Infinity's oral immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase-gamma (PI3K-gamma). Dr. Kutok will join the executive leadership team and report to Ms. Adelene Perkins, Infinity's chair and chief executive officer. Dr. Kutok joined the company in 2010 and was promoted to vice president, biology and translational science in 2013. Prior to joining Infinity in 2010, Dr. Kutok was an associate professor of pathology at Harvard Medical School and Brigham and Women's Hospital.